GAITHERSBURG, Md.--(BUSINESS WIRE)--Expression Pathology Inc. (EPI), a leader in tissue proteomics, announced that researchers at Tokyo Medical University, using the company’s tissue microproteomics technologies, identified protein biomarkers associated with lung cancer metastasis, which were further studied for correlation to clinical outcomes. The researchers used EPI’s Liquid Tissue® reagents and Director™ laser microdissection slides to analyze formalin-fixed paraffin-embedded (FFPE) tissue samples by mass spectrometry.
